ProSight is a medical device startup spun out of the Weizmann Institute of Science, developing a real-time ex-vivo biopsy samples scanner, potentially transforming prostate cancer diagnosis based on new, never-used-before biomarkers, addressing the limitations in all biopsy procedures. Need: Current methods in prostate cancer biopsy often miss tumors and lead to unnecessary procedures, resulting in patient anxiety, delayed treatment, and increased healthcare costs. Science: Zinc depletion in the prostate is the most accurate cancer biomarker known to science. (~1,800 articles in the last 25 Yrs) Novelty: Fast X-ray fluorescence scanning of the fresh biopsy samples during biopsy, for computing the cancer severity Clinical Use and Impact: During-biopsy, real-time cancer grading of the biopsy samples, eliminating randomness, allowing real-time guidance to suspicious regions - thus harvesting the most relevant samples. ~ Doubling Detection Rate and Cancer Characterization Accuracy Minimizing over/under treatment; earlier detection (Zn depletion precedes other cancer signs) maximizing the likelihood of detecting all tumors in the 1st biopsy, Readiness: Prototype; Patents (one granted); Successful Clinical studies in local MCs; Regulatory Strategy (510k) in place for the 1st release, backed by Hogan Lovells; money injection to date - ca $6M (bootstrap mode); article published (https://www.mdpi.com/2075-4418/13/3/424/pdf) Plans: Raising round A - $8M (the Israeli Innovation Authority will add non-dilutive funding ~$4M); Completion of product development (first generation) and FDA submission - in 12 months following investment; FDA clearance and 1st product launch - 18 months; Reimbursement and start-of-sales - 24 months. Team: High-tech veterans with diverse executive roles, led a number of breakthrough projects. Capable of initiating all critical paths. Achievable goal: Become Standard of Care in prostate cancer biopsy and diagnosis - a $10Bn market.